Literature DB >> 17537119

Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy.

Caroline E Fife1, Cem Buyukcakir, Gordon Otto, Paul Sheffield, Tommy Love, Robert Warriner.   

Abstract

The objectives of this study were to report outcomes of a large number of patients receiving hyperbaric oxygen therapy (HBO(2)T) for diabetic lower-extremity ulcers, and to identify likely outcome predictors. Five hyperbaric facilities supplied data on 1,006 patients. A sixth clinic served as a validation sample for the regression-based prediction model, and later additional data from Memorial Hermann Hospital were added. The severity of lower-extremity lesions was assessed upon initiation of HBO(2)T using the Modified Wagner scale, and the outcome described as healed, partially healed, not improved, amputated, or died. Overall, 73.8% of patients improved (granulated or healed). Factors significantly related to outcome included renal failure, pack-year smoking history, transcutaneous oximetry, number of HBO(2)T treatments, and interruption of treatment regimen. Number of treatments per week and treatment pressure (2.0 vs. 2.4 atmospheres absolute) were not significant factors in outcome. Concomitant administration of autologous growth factor gel did not improve outcome. A multiple regression model was fitted to the data that can be used to predict the outcome of diabetic patients undergoing HBO(2)T. Given the high cost of amputation and rehabilitation, these data suggest that hyperbaric oxygen treatment should be an important adjunctive therapy to heal lower-extremity lesions, especially those with a Wagner grade of 3 or higher.

Entities:  

Mesh:

Year:  2007        PMID: 17537119     DOI: 10.1111/j.1524-475X.2007.00234.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  20 in total

1.  Medical school hotline: Hyperbaric Treatment Center of the University of Hawai'i: 2012 update.

Authors:  Richard W Smerz; Frank Farm
Journal:  Hawaii J Med Public Health       Date:  2012-04

Review 2.  Diabetes mellitus and burns. Part II-outcomes from burn injuries and future directions.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

3.  A retrospective study of diabetic foot ulcers treated with hyperbaric oxygen therapy.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-02-28       Impact factor: 3.315

Review 4.  Hyperbaric oxygen, vasculogenic stem cells, and wound healing.

Authors:  Katina M Fosen; Stephen R Thom
Journal:  Antioxid Redox Signal       Date:  2014-05-19       Impact factor: 8.401

Review 5.  Hyperbaric oxygen: its mechanisms and efficacy.

Authors:  Stephen R Thom
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

Review 6.  What is the role of hyperbaric oxygen in the management of diabetic foot disease?

Authors:  Magnus Löndahl; Katarina Fagher; Per Katzman
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

7.  Inhibition of stromal cell-derived factor-1α further impairs diabetic wound healing.

Authors:  Dustin M Bermudez; Junwang Xu; Benjamin J Herdrich; Antoneta Radu; Marc E Mitchell; Kenneth W Liechty
Journal:  J Vasc Surg       Date:  2011-01-06       Impact factor: 4.268

Review 8.  Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-07-02       Impact factor: 3.315

9.  Can major amputation rates be decreased in diabetic foot ulcers with hyperbaric oxygen therapy?

Authors:  Ahmet Kaya; Figen Aydin; Taskin Altay; Levent Karapinar; Hasan Ozturk; Cengiz Karakuzu
Journal:  Int Orthop       Date:  2008-07-25       Impact factor: 3.075

Review 10.  Vascular assessment of wound healing: a clinical review.

Authors:  William W Li; Marissa J Carter; Elad Mashiach; Stephen D Guthrie
Journal:  Int Wound J       Date:  2016-07-04       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.